{"id":53524,"date":"2026-01-10T21:49:50","date_gmt":"2026-01-10T13:49:50","guid":{"rendered":"https:\/\/flcube.com\/?p=53524"},"modified":"2026-01-10T21:49:51","modified_gmt":"2026-01-10T13:49:51","slug":"medilink-licenses-b7h3-adc-yl201-to-roche-in-850-million-global-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53524","title":{"rendered":"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal"},"content":{"rendered":"\n<p><strong>MediLink Therapeutics<\/strong> announced a <strong>collaboration and exclusive licensing agreement<\/strong> with <strong>Roche (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX: ROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>)<\/strong> for <strong>YL201<\/strong>, a <strong>B7H3\u2011targeting antibody\u2011drug conjugate (ADC)<\/strong> in development for multiple solid tumor types. Roche gains <strong>exclusive worldwide rights<\/strong> (excluding Greater China) for <strong>USD\u202f570\u202fmillion<\/strong> in upfront and near\u2011term milestone payments, with total deal value exceeding <strong>USD\u202f850\u202fmillion<\/strong> including development, regulatory, and commercial milestones plus tiered royalties. This deepens the partnership that began with <strong>YL211 (c\u2011Met ADC)<\/strong> in January\u202f2024.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>MediLink Therapeutics<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Roche (SWX: ROG, OTCMKTS: RHHBY)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>YL201 (B7H3\u2011targeted ADC)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Worldwide excluding Greater China (mainland, HK, Macau)<\/td><\/tr><tr><td><strong>Upfront\/Near\u2011Term<\/strong><\/td><td><strong>USD\u202f570\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>&gt; USD\u202f850\u202fmillion<\/strong> (including milestones &amp; royalties)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered on net sales outside China<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Multinational trials ongoing (SCLC, NPC, ESCC)<\/td><\/tr><tr><td><strong>Designations<\/strong><\/td><td>FDA Breakthrough Therapy (SCLC) + 3 Orphan Drug Designations (SCLC, NPC, ESCC)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-b7h3-targeting-adc\">Technology Profile: B7H3\u2011Targeting ADC<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: YL201 is an <strong>antibody\u2011drug conjugate<\/strong> that delivers a <strong>cytotoxic payload<\/strong> to <strong>B7H3\u2011expressing tumor cells<\/strong>. B7H3 is overexpressed in <strong>multiple solid tumors<\/strong> but has <strong>limited expression in normal tissues<\/strong>, offering a <strong>therapeutic window<\/strong> for targeted therapy.<\/p>\n\n\n\n<p><strong>Clinical Pipeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Small cell lung cancer (SCLC)<\/strong>: Phase\u202fI\/II multinational trials<\/li>\n\n\n\n<li><strong>Nasopharyngeal carcinoma (NPC)<\/strong>: Phase\u202fI\/II<\/li>\n\n\n\n<li><strong>Esophageal squamous cell carcinoma (ESCC)<\/strong>: Phase\u202fI\/II<\/li>\n<\/ul>\n\n\n\n<p><strong>Regulatory Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA Breakthrough Therapy Designation<\/strong> for SCLC (fast\u2011track pathway)<\/li>\n\n\n\n<li><strong>3 Orphan Drug Designations<\/strong>: SCLC, NPC, ESCC (7\u2011year market exclusivity)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-b7h3-targeted-therapies\">Market Opportunity: B7H3\u2011Targeted Therapies<\/h2>\n\n\n\n<p><strong>Global Market<\/strong>: B7H3 ADCs target <strong>\u00a580\u2011100\u202fbillion<\/strong> (US$11\u201114\u202fbillion) solid tumor market across <strong>SCLC, NPC, ESCC, and lung cancer<\/strong>.<\/p>\n\n\n\n<p><strong>SCLC Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Incidence<\/strong>: <strong>300,000<\/strong> new cases annually<\/li>\n\n\n\n<li><strong>China<\/strong>: <strong>130,000<\/strong> new cases (40% of global)<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Chemo\u2011immunotherapy (ORR\u202f\u2248\u202f60%, mOS\u202f\u2248\u202f12\u202fmonths)<\/li>\n\n\n\n<li><strong>YL201 Potential<\/strong>: Early data suggests <strong>ORR\u202f>\u202f70%<\/strong> in relapsed\/refractory SCLC<\/li>\n<\/ul>\n\n\n\n<p><strong>NPC &amp; ESCC<\/strong>: <strong>\u00a515\u202fbillion<\/strong> combined China market with <strong>high unmet need<\/strong> for targeted therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For MediLink<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non\u2011Dilutive Capital<\/strong>: <strong>USD\u202f570\u202fmillion<\/strong> funds YL201 China development and platform expansion<\/li>\n\n\n\n<li><strong>Global Validation<\/strong>: Roche partnership <strong>validates B7H3 platform<\/strong>, attracting future deals<\/li>\n\n\n\n<li><strong>Platform Leverage<\/strong>: Builds on <strong>YL211 (c\u2011Met ADC)<\/strong> success, demonstrating <strong>repeatable execution<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>For Roche<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Gap Fill<\/strong>: Addresses <strong>ADC pipeline shortage<\/strong> after <strong>Kadcyla<\/strong> patent expiry (2025)<\/li>\n\n\n\n<li><strong>China Access<\/strong>: Partners with <strong>proven Chinese innovator<\/strong> for <strong>cost\u2011effective development<\/strong><\/li>\n\n\n\n<li><strong>Multi\u2011Indication Asset<\/strong>: B7H3 expression across <strong>5+ tumor types<\/strong> offers <strong>significant lifecycle value<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Target<\/th><th>Stage<\/th><th>Indication(s)<\/th><\/tr><\/thead><tbody><tr><td><strong>YL201<\/strong><\/td><td><strong>MediLink \u2192 Roche<\/strong><\/td><td>B7H3 ADC<\/td><td>Phase\u202fI\/II (BTD)<\/td><td>SCLC, NPC, ESCC<\/td><\/tr><tr><td><strong>Enoblituzumab<\/strong><\/td><td>MacroGenics<\/td><td>B7H3 mAb<\/td><td>Phase\u202fIII<\/td><td>Prostate, lung<\/td><\/tr><tr><td><strong>MGC018<\/strong><\/td><td>MacroGenics<\/td><td>B7H3 ADC<\/td><td>Phase\u202fI<\/td><td>Solid tumors<\/td><\/tr><tr><td><strong>DS\u20117300a<\/strong><\/td><td>Daiichi\/AstraZeneca<\/td><td>B7H3 ADC<\/td><td>Phase\u202fI<\/td><td>SCLC, NSCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: YL201 is <strong>6\u201112 months ahead<\/strong> of competitors in <strong>SCLC<\/strong> with <strong>Breakthrough Designation<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercialization-pathway\">Development &amp; Commercialization Pathway<\/h2>\n\n\n\n<p><strong>MediLink\u2019s Role<\/strong>: Continue <strong>China development<\/strong> and <strong>global supply<\/strong> of drug substance.<\/p>\n\n\n\n<p><strong>Roche\u2019s Role<\/strong>: Lead <strong>global clinical trials, regulatory submissions, and commercialization<\/strong> (ex\u2011China).<\/p>\n\n\n\n<p><strong>Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China NDA<\/strong>: MediLink plans submission <strong>H2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Global Phase\u202fIII<\/strong>: Roche to initiate <strong>Q4\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Commercial Launch<\/strong>: <strong>2028<\/strong> (China), <strong>2029\u20112030<\/strong> (ex\u2011China)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h2>\n\n\n\n<p><strong>MediLink Upside<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Cash<\/strong>: <strong>USD\u202f570\u202fmillion<\/strong> (non\u2011dilutive)<\/li>\n\n\n\n<li><strong>Milestone Potential<\/strong>: <strong>USD\u202f280\u202fmillion<\/strong> remaining (development\/regulatory)<\/li>\n\n\n\n<li><strong>Royalty Stream<\/strong>: <strong>Mid\u2011teens to low\u2011twenties<\/strong> on ex\u2011China sales; potential <strong>USD\u202f150\u2011250\u202fmillion<\/strong> annually at peak<\/li>\n\n\n\n<li><strong>Platform Value<\/strong>: Validates <strong>2\u20113 additional ADC assets<\/strong> in pre\u2011clinical stage<\/li>\n<\/ul>\n\n\n\n<p><strong>Roche Economics<\/strong>: In\u2011licensing at <strong>Phase\u202fI\/II stage<\/strong> vs. internal ADC development <strong>saves 3\u20114 years<\/strong> and <strong>USD\u202f500\u2011700\u202fmillion<\/strong> in discovery costs.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding YL201\u2019s clinical development, regulatory approvals, market opportunities, and financial milestones. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, regulatory review timelines, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,372,940,163,939],"class_list":["post-53524","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-medilink-therapeutics","tag-otcmkts-rhhby","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY) for YL201, a B7H3\u2011targeting antibody\u2011drug conjugate (ADC) in development for multiple solid tumor types. Roche gains exclusive worldwide rights (excluding Greater China) for USD\u202f570\u202fmillion in upfront and near\u2011term milestone payments, with total deal value exceeding USD\u202f850\u202fmillion including development, regulatory, and commercial milestones plus tiered royalties. This deepens the partnership that began with YL211 (c\u2011Met ADC) in January\u202f2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53524\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal\" \/>\n<meta property=\"og:description\" content=\"MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY) for YL201, a B7H3\u2011targeting antibody\u2011drug conjugate (ADC) in development for multiple solid tumor types. Roche gains exclusive worldwide rights (excluding Greater China) for USD\u202f570\u202fmillion in upfront and near\u2011term milestone payments, with total deal value exceeding USD\u202f850\u202fmillion including development, regulatory, and commercial milestones plus tiered royalties. This deepens the partnership that began with YL211 (c\u2011Met ADC) in January\u202f2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53524\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-10T13:49:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-10T13:49:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53524#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53524\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal\",\"datePublished\":\"2026-01-10T13:49:50+00:00\",\"dateModified\":\"2026-01-10T13:49:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53524\"},\"wordCount\":616,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"MediLink Therapeutics\",\"OTCMKTS: RHHBY\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53524#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53524\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53524\",\"name\":\"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-10T13:49:50+00:00\",\"dateModified\":\"2026-01-10T13:49:51+00:00\",\"description\":\"MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY) for YL201, a B7H3\u2011targeting antibody\u2011drug conjugate (ADC) in development for multiple solid tumor types. Roche gains exclusive worldwide rights (excluding Greater China) for USD\u202f570\u202fmillion in upfront and near\u2011term milestone payments, with total deal value exceeding USD\u202f850\u202fmillion including development, regulatory, and commercial milestones plus tiered royalties. This deepens the partnership that began with YL211 (c\u2011Met ADC) in January\u202f2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53524#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53524\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53524#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal - Insight, China&#039;s Pharmaceutical Industry","description":"MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY) for YL201, a B7H3\u2011targeting antibody\u2011drug conjugate (ADC) in development for multiple solid tumor types. Roche gains exclusive worldwide rights (excluding Greater China) for USD\u202f570\u202fmillion in upfront and near\u2011term milestone payments, with total deal value exceeding USD\u202f850\u202fmillion including development, regulatory, and commercial milestones plus tiered royalties. This deepens the partnership that began with YL211 (c\u2011Met ADC) in January\u202f2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53524","og_locale":"en_US","og_type":"article","og_title":"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal","og_description":"MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY) for YL201, a B7H3\u2011targeting antibody\u2011drug conjugate (ADC) in development for multiple solid tumor types. Roche gains exclusive worldwide rights (excluding Greater China) for USD\u202f570\u202fmillion in upfront and near\u2011term milestone payments, with total deal value exceeding USD\u202f850\u202fmillion including development, regulatory, and commercial milestones plus tiered royalties. This deepens the partnership that began with YL211 (c\u2011Met ADC) in January\u202f2024.","og_url":"https:\/\/flcube.com\/?p=53524","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-10T13:49:50+00:00","article_modified_time":"2026-01-10T13:49:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53524#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53524"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal","datePublished":"2026-01-10T13:49:50+00:00","dateModified":"2026-01-10T13:49:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53524"},"wordCount":616,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","MediLink Therapeutics","OTCMKTS: RHHBY","Roche","SWX: ROP"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53524#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53524","url":"https:\/\/flcube.com\/?p=53524","name":"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-10T13:49:50+00:00","dateModified":"2026-01-10T13:49:51+00:00","description":"MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY) for YL201, a B7H3\u2011targeting antibody\u2011drug conjugate (ADC) in development for multiple solid tumor types. Roche gains exclusive worldwide rights (excluding Greater China) for USD\u202f570\u202fmillion in upfront and near\u2011term milestone payments, with total deal value exceeding USD\u202f850\u202fmillion including development, regulatory, and commercial milestones plus tiered royalties. This deepens the partnership that began with YL211 (c\u2011Met ADC) in January\u202f2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53524#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53524"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53524#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53524"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53524\/revisions"}],"predecessor-version":[{"id":53525,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53524\/revisions\/53525"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}